AsymBio
Summary active Updated Aug 5, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
AsymBio is a biologics-focused Contract Development and Manufacturing Organization (CDMO) headquartered in China and a subsidiary of Asymchem Group 123. The company provides end-to-end services spanning early-stage and process development, toxicology, clinical manufacturing, and large-scale commercial manufacturing, with particular expertise in antibody-drug conjugates and related biologics 12. AsymBio generated approximately US$70 million in revenue in 2025, with Q1 2026 revenue exceeding US$21 million 13.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-08-04 | Capital Injection | $184M | Asymchem Group | Hillhouse Qirui 123 |
The capital injection totaled RMB 1.2397 billion (approximately US$184 million), with parent Asymchem Group contributing RMB 1.05 billion (~US$156 million) and Hillhouse Qirui contributing RMB 177 million (~US$26 million); other unnamed investors also participated 123. Following the transaction, Asymchem Group’s ownership stake in AsymBio increases to 83.4965% 12. Proceeds will support capacity ramp-up, R&D platform investments, GMP manufacturing lines, and high-containment facilities 123.
What Investors Say
No independently sourced investor quotes about the round available at time of profile creation.
What Founders Say
No independently sourced founder testimonials found at time of profile creation.
Sources
-
PR Newswire, “AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth,” August 4, 2026, accessed August 2026. https://www.prnewswire.com/news-releases/asymbio-secures-us184-million-capital-injection-to-support-long-term-growth-302842349.html↩↩↩↩↩↩↩
-
Pharmaceutical Technology, “AsymBio to secure $184m to support growth in biologics manufacturing,” August 5, 2026, accessed August 2026. https://www.pharmaceutical-technology.com/news/asymbio-growth-biologics-manufacturing/↩↩↩↩↩↩
-
BioSpectrum Asia, “China’s AsymBio secures $184 M capital injection to support long-term growth,” August 2026, accessed August 2026. https://www.biospectrumasia.com/news/40/28152/chinas-asymbio-secures-184-m-capital-injection-to-support-long-term-growth.html↩↩↩↩↩